OrthoPediatrics (NASDAQ:KIDS) Given “Buy” Rating at BTIG Research

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a research report issued on Friday,Benzinga reports. They presently have a $24.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 59.36% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Truist Financial upped their price target on shares of OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Tuesday, April 21st. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research report on Tuesday, January 27th. Finally, Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.78.

OrthoPediatrics Stock Up 2.9%

Shares of OrthoPediatrics stock opened at $15.06 on Friday. The company has a fifty day moving average price of $16.73 and a 200 day moving average price of $17.28. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $23.70. The stock has a market cap of $386.89 million, a price-to-earnings ratio of -8.91 and a beta of 1.16.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%. The firm had revenue of $59.36 million during the quarter, compared to analysts’ expectations of $58.29 million. Equities research analysts forecast that OrthoPediatrics will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, insider Gregory A. Odle sold 8,433 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total value of $145,469.25. Following the completion of the transaction, the insider directly owned 187,735 shares of the company’s stock, valued at $3,238,428.75. This represents a 4.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Fred Hite sold 12,993 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $224,129.25. Following the completion of the transaction, the chief financial officer directly owned 277,477 shares of the company’s stock, valued at approximately $4,786,478.25. The trade was a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,171 shares of company stock worth $1,003,450 over the last quarter. Company insiders own 32.70% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KIDS. Millennium Management LLC boosted its position in OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after buying an additional 452,840 shares during the last quarter. Prosight Management LP raised its stake in shares of OrthoPediatrics by 319.2% in the 3rd quarter. Prosight Management LP now owns 308,707 shares of the company’s stock valued at $5,720,000 after purchasing an additional 235,060 shares in the last quarter. Deerfield Management Company L.P. raised its stake in shares of OrthoPediatrics by 1,153.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock valued at $3,597,000 after purchasing an additional 178,623 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of OrthoPediatrics by 303.3% in the 4th quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock valued at $3,542,000 after purchasing an additional 150,000 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of OrthoPediatrics in the 4th quarter valued at about $1,953,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.